David A. Santos
Net Worth
Last updated:
What is David A. Santos net worth?
The estimated net worth of Mr. David A. Santos is at least $15,532,398 as of 5 Feb 2024. He owns shares worth $13,446,958 as insider, has earned $25,440 from insider trading and has received compensation worth at least $2,060,000 in Rigel Pharmaceuticals, Inc..
What is the salary of David A. Santos?
Mr. David A. Santos salary is $1,030,000 per year as Executive Vice President & Chief Commercial Officer in Rigel Pharmaceuticals, Inc..
How old is David A. Santos?
Mr. David A. Santos is 62 years old, born in 1963.
What stocks does David A. Santos currently own?
As insider, Mr. David A. Santos owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | Executive Vice President & Chief Commercial Officer | 349,093 | $38.52 | $13,446,958 |
What does Rigel Pharmaceuticals, Inc. do?
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
David A. Santos insider trading
Rigel Pharmaceuticals, Inc.
Mr. David A. Santos has made 3 insider trades between 2023-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,918 units of RIGL stock worth $10,167 on 5 Feb 2024.
The largest trade he's ever made was exercising 8,918 units of RIGL stock on 5 Feb 2024. As of 5 Feb 2024 he still owns at least 349,093 units of RIGL stock.
Rigel Pharmaceuticals key executives
Rigel Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Wolfgang Dummer M.D., Ph.D. (59) Executive Vice President & Chief Medical Officer
- Mr. David A. Santos (62) Executive Vice President & Chief Commercial Officer
- Mr. Dean L. Schorno CPA (62) Executive Vice President & Chief Financial Officer
- Mr. Raul R. Rodriguez (64) Pres, Chief Executive Officer & Director
- Ms. Dolly A. Vance (60) Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec.